RGS22

RGS22 is a regulator of G-protein signaling that restrains Gα12/13-family-driven cytoskeletal remodeling and cell motility across reproductive, neural, and oncogenic contexts (PMID:18703424, PMID:26323264, PMID:39400871). It physically associates with the heterotrimeric G-protein α subunits GNA12, GNA13, and GNA11, and through coupling to GNA12/13 it delays lysophosphatidic acid (LPA)-induced F-actin stress fiber formation and cell deformation, thereby suppressing migration; loss of RGS22 increases motility and invasive potential in pancreatic, esophageal, and hepatocellular carcinoma cells (PMID:18703424, PMID:26323264, PMID:21533872, PMID:29038925). In the brain, RGS22 is expressed specifically in ependymal cells, where it restrains excessive LPAR signaling to support ciliogenesis; its loss causes severe congenital hydrocephalus that is alleviated by pharmacological LPAR blockade, establishing RGS22 as an upstream negative regulator of the LPAR axis (PMID:39400871). During spermiogenesis, RGS22 partitions to the nucleus via its N-terminal domain and facilitates the nuclear translocation of GNA13 from the elongated spermatid stage onward (PMID:18703424). Its expression is transcriptionally activated by the transcription factor YY1, and YY1-driven RGS22 upregulation suppresses tumor cell proliferation, migration, and invasion in vitro and in vivo (PMID:36380881).

1. 2008 Medium

   Established RGS22's first physical partners and a developmental role by showing it binds Gα12/13/11 subunits and escorts GNA13 to the nucleus during sperm maturation.

   Evidence Co-immunoprecipitation, GFP-fusion subcellular tracking, and immunofluorescence in testis/spermatid systems

   PMID:18703424

   Open questions at the time

   • Direct GAP/RGS catalytic activity on the Gα subunits not demonstrated
   • Mechanism by which RGS22 drives GNA13 nuclear import unresolved
   • Functional consequence for sperm physiology shown only by correlation with abnormal spermatozoa
2. 2011 Medium

   Defined RGS22 as a suppressor of cancer cell invasion, linking its loss to metastatic phenotype.

   Evidence RGS22 overexpression with migration/invasion assays and tumor tissue immunohistochemistry in esophageal cancer cells

   PMID:21533872

   Open questions at the time

   • Single functional readout per condition
   • Molecular mechanism of invasion suppression not addressed in this study
3. 2015 Medium

   Connected the anti-migratory role to a signaling mechanism by showing RGS22 couples to GNA12/13 to block LPA-induced stress fiber formation.

   Evidence Pull-down, co-IP, wound-healing, and F-actin staining with gain- and loss-of-function in BXPC-3 pancreatic cancer cells

   PMID:26323264

   Open questions at the time

   • Does not establish whether RGS22 acts as a GAP toward Gα12/13
   • Downstream effectors between Gα12/13 and the actin cytoskeleton not mapped
4. 2017 Low

   Placed RGS22 downstream of a microRNA regulatory input, implicating its repression in liver cancer progression.

   Evidence miR-1260b overexpression, RGS22 knockdown, and migration/invasion/proliferation assays in HCC cell lines

   PMID:29038925

   Open questions at the time

   • Direct targeting inferred rather than rigorously demonstrated in the abstract
   • Limited mechanistic detail beyond phenotype
   • Single lab
5. 2022 Medium

   Identified an upstream transcriptional activator, showing YY1 drives RGS22 expression to enforce tumor-suppressive phenotypes.

   Evidence YY1 manipulation with RGS22 gain/loss-of-function in PDAC lines plus xenograft model

   PMID:36380881

   Open questions at the time

   • Direct YY1 binding to the RGS22 promoter not detailed
   • Link between YY1-RGS22 axis and Gα12/13 signaling not directly tested
6. 2024 High

   Demonstrated a physiological, organ-specific function by showing ependymal RGS22 restrains LPAR signaling to maintain ciliogenesis, with loss causing hydrocephalus rescuable by LPAR blockade.

   Evidence Constitutive and nervous-system conditional knockout mice and rats with histology, immunofluorescence, and pharmacological LPAR rescue

   PMID:39400871

   Open questions at the time

   • Whether RGS22 acts directly on a specific Gα subunit downstream of LPAR in ependymal cells not biochemically resolved
   • Molecular link between LPAR hyperactivation and cilia loss not fully mapped

• Whether RGS22 possesses canonical RGS GAP catalytic activity toward its bound Gα subunits, or acts purely as a scaffold/sequestering regulator, remains unresolved.
• No reconstituted GAP assay reported
• No structural model of the RGS22-Gα interface
• Substrate specificity among GNA11/12/13 not biochemically dissected